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ABSTRACT
Nasopharyngeal Streptococcus pneumoniae isolates colonising young children are representative of
isolates causing clinical disease. This study determined the frequency of macrolide-non-susceptible
pneumococci, as well as their phenotypic and genotypic characteristics, among pneumococci collected
during two cross-sectional surveillance studies of the nasopharynx of 2847 children attending day-care
centres in the Athens metropolitan area during 2000 and 2003. In total, 227 macrolide-non-susceptible
pneumococcal isolates were studied. Increases in macrolide non-susceptibility, from 23% to 30.3%
(p <0.05), and in macrolide and penicillin co-resistance, from 3.4% to 48.6% (p <0.001), were identified
during the study period. The M resistance phenotype, associated with the presence of the mef(A) ⁄ (E)
gene, predominated in both surveys, and isolates carrying both mef(A) ⁄ (E) and erm(AM) were identified,
for the first time in Greece, among the isolates from the 2003 survey. Pulsed-field gel electrophoresis
analysis of the isolates from the 2000 survey indicated the spread of a macrolide- and penicillin-resistant
clone among day-care centres. The serogroups identified most commonly in the study were 19F, 6A, 6B,
14 and 23F, suggesting that the theoretical protection of the seven-valent conjugate vaccine against
macrolide-non-susceptible isolates was c. 85% during both study periods.
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INTRODUCTION
Macrolides have been used widely for empirical
treatment of community-acquired respiratory
tract infections because of their efficacy against
both Streptococcus pneumoniae and atypical respir-
atory pathogens. However, increasing use of
macrolides has been associated with an increase
in macrolide resistance [1]. Two main macrolide
resistance mechanisms have been identified in
pneumococci: energy-dependent efflux, associ-
ated with the presence of mef genes [2], and
target site modification, associated with the erm
gene family [3]. Mechanisms encountered less
frequently involve mutations of ribosomal pro-
teins or 23S rRNA genes [4]. There is now
emerging evidence that macrolide resistance in
S. pneumoniae results in clinical failure in cases of
both otitis media and pneumonia [5–9].
The nasopharynx of colonised individuals is
the main reservoir of pneumococci in the
community. Most young children become carri-
ers at some point, and are responsible for
spreading pneumococci to other children, espe-
cially in the crowded environment of a day-care
centre. Although only a small percentage of
colonised children will develop an invasive
infection, pneumococcal nasopharyngeal isolates
reflect the strains circulating currently in a
particular community and may enable the cap-
sular types causing invasive disease to be
predicted [10,11].
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The aims of the present study were to determine
the prevalence of macrolide non-susceptibility,
and the phenotypic and genotypic characteris-
tics of macrolide-non-susceptible S. pneumon-
iae, among isolates colonising the nasopharynx of
healthy children in the Athens metropolitan
area, Greece. Data from the present study were
expected to contribute to an understanding of
the epidemiology of macrolide resistance in this
community, and to guide empirical treatment
of common community-acquired pneumococcal
infections.
MATERIALS AND METHODS
Study population
The S. pneumoniae isolates were collected during two cross-
sectional surveillance studies conducted in the greater Athens
metropolitan area during the first trimester of 2000 and 2003.
Nasopharyngeal samples were obtained from healthy chil-
dren, aged 1–6 years, who attended day-care centres located in
various parts of the Athens metropolitan area. Only children
whose parents had signed a consent form were included in the
study.
Trained physicians obtained perinasal specimens of naso-
pharyngeal secretions using a cotton-tipped flexible alumin-
ium wire swab (Medical Wire & Equipment, Corsham, UK).
Specimens were plated immediately on Mueller–Hinton II
agar (Becton Dickinson, Sparks, MD, USA) supplemented with
sheep blood 5% v ⁄v. The plates were enclosed in Gas Pak CO2
Pouches (Becton Dickinson) and sent to the microbiology
laboratory for incubation.
Bacteria
S. pneumoniae isolates were identified on the basis of colony
morphology, appearance following Gram’s stain, susceptibility
to optochin (5-lg disk; Becton Dickinson), solubility in bile and
a latex agglutination test (Slidex pneumo-kit; bioMe´rieux,
Marcy L’Etoile, France). Confirmed pneumococci were stored
in Todd Hewitt broth (Becton Dickinson) supplemented with
Bacteriological agar 0.3% w ⁄v (Gibco BRL, Paisley, UK) and
glycerine 3% v ⁄v, and were kept at )80C until required for
further testing.
Susceptibility testing
MICs of benzylpenicillin, ampicillin, erythromycin, cefurox-
ime, ceftriaxone, cefepime, moxifloxacin, linezolid, vancomy-
cin and quinupristin–dalfopristin were determined by Etest
(AB Biodisk, Solna, Sweden) on Mueller–Hinton II agar
supplemented with sheep blood 5% v ⁄v. Results were read
after incubation for 20–24 h in CO2 5% v ⁄v and were
interpreted according to the manufacturer’s instructions.
Results falling between serial two-fold dilutions were round-
ed-up to the next highest concentration. Telithromycin
(Aventis, Vitry, France) MICs were determined by the agar-
dilution method in ambient air, and results were interpreted
according to CLSI criteria [12]. S. pneumoniae ATCC 49619
was used for quality control as a reference strain. All of
the erythromycin-non-susceptible strains were characterised
further.
Serotyping
Serotyping was performed with the Quellung reaction using
the 12 pooled antisera contained in the Pneumotest panel, as
well as selected factor sera (Statens Serum Institut, Copen-
hagen, Denmark).
Macrolide resistance phenotype
The macrolide resistance phenotype was determined by the
triple disk-diffusion method [13]. An MLSB phenotype was
defined as resistance to erythromycin, clindamycin and quin-
upristin (streptogramin B), and an M phenotype was defined
as resistance to erythromycin alone.
Pulsed-field gel electrophoresis (PFGE)
The erythromycin-non-susceptible isolates from the 2000
survey were subjected to molecular typing by PFGE [14]. A
PFGE-based clonal group was defined as a group of isolates
with genetically-related PFGE patterns, as described by
Tenover et al. [15].
Detection of macrolide resistance mechanisms by DNA
amplification
Genomic DNA isolation was performed with a QIAamp
DNA Mini Kit (Qiagen, Hilden, Germany), following the
manufacturer’s guidelines. To ensure genomic DNA integrity
for all isolates studied, the 16S)23S spacer region of
S. pneumoniae (337 bp) was amplified by PCR [16]. The
isolates were screened by multiplex PCR for rRNA erm
methylases and for genes coding for inactivating enzymes or
macrolide efflux pumps with primers for erm(A), erm(B),
erm(C), msr(A) ⁄msr(B), mph(A), mph(B), ere(A), ere(B) and
mef(A) ⁄ (E) as described by Sutcliffe et al. [17], and for
mph(C) as described by Tait-Kamradt et al. [18]. Discrimin-
ation between subtypes mef(A) and mef(E), which are 90%
identical at the nucleotide level, was not attempted, and
‘mef(A) ⁄ (E)’ was used to designate the presence of the mef
gene in the isolates of this study. The erm(AM) gene was not
amplified by the set of primers used for the amplification of
the erm(B) gene (despite 99% identity at the nucleotide level)
because of A to G and G to A transitions at the site of
annealing of the forward primer. The presence of erm(AM)
was determined by PCR with gene-specific internal primers
(5¢-TTGGAACAGGTAAAGGGCATT and 5¢-TTGGCGTG-
TTTCATTGCTTG). S. pneumoniae BM4200 [19] and genomic
DNA from S. pneumoniae 02J1175 [20] were used as positive
controls for PCR amplification of erm(AM) and mef(A) ⁄ (E),
respectively. All primers were synthesised by MWG-Biotech
(Ebersbery, Germany).
Statistical analysis
The data were analysed by the chi-square test with Yates’
correction and by Fisher’s exact test, as appropriate. Two-
tailed p values £0.05 were considered to be significant.
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RESULTS
Bacteria and their susceptibilities
The results in Table 1 summarise the study
population and the isolates of S. pneumoniae that
were recovered. The day-care centres that were
chosen to participate in the study were represen-
tative of various socio-economic parts of the
Athens metropolitan area, and 25 centres were
common to both study periods.
Of 89 macrolide-non-susceptible isolates (eryth-
romycin MIC ‡2 mg ⁄L) recovered during 2000, 31
(34.8%) were also non-susceptible to penicillin,
and three isolates were resistant to macrolides,
penicillin and cefepime. All 31 macrolide- and
penicillin-non-susceptible isolates were suscept-
ible to moxifloxacin, telithromycin, linezolid,
vancomycin and quinupristin–dalfopristin. Sev-
enty-four of the 89 macrolide-non-susceptible
isolates from 2000 were available for further
phenotypic and genotypic characterisation (see
below). Of the 138 macrolide-non-susceptible
isolates recovered during 2003, 106 (76.8%) were
also non-susceptible to penicillin, 67 (48.6%) were
resistant to three antimicrobial agents (macrolides,
penicillin and cefuroxime), and ten were resistant
to more than three antimicrobial agents (macro-
lides, penicillin, cefuroxime and ceftriaxone).
Table 1 also summarises the genotypic analysis
results for the erythromycin-non-susceptible iso-
lates from both study periods. All isolates pos-
sessing only a mef(A) ⁄ (E) resistance determinant
displayed the M phenotype, whereas all isolates
that were PCR-positive for erm(AM) had the
constitutive MLSB phenotype. The three isolates
that harboured both the erm(AM) and the mef(A) ⁄
(E) genes were assigned to the constitutive MLSB
phenotype. The antimicrobial susceptibilities of
the S. pneumoniae isolates with different resistance
genotypes are shown in Tables 2 and 3. The MICs
of erythromycin, penicillin, cefuroxime and cef-
triaxone for the three isolates with the dual
resistance mechanism were 64–>256, 0.064–4,
0.25–8 and 0.125–2 mg ⁄L, respectively. All three
of these isolates were susceptible to moxifloxacin,
telithromycin and linezolid. In both surveys, the
majority of isolates that were non-susceptible to
both macrolides and penicillin belonged to the
mef(A) ⁄ (E) genotype (74% in 2000; 74.5% in 2003).
The same was observed for isolates that were non-
susceptible to more than three antibiotics (100%
in 2000; 73% in 2003). No other macrolide
resistance genes were detected.
PFGE
The PFGE results for the 74 macrolide-non-sus-
ceptible isolates from the year 2000 survey are
Table 1. Summary of the demographics and susceptibilit-
ies of the Streptococcus pneumoniae isolates investigated
during the 2000 and 2003 surveys
Year 2000 Year 2003
Participating day-care centres (n) 49 36
Children enrolled (n) 1451 1396
No. of isolates recovered 461 485
Carriage rate (%) 31.8 34.7
Isolates tested (n) 387 456
Macrolide-non-susceptible isolates n (%) 89 (23) 138 (30.3)
mef(A) ⁄ (E)-positive isolates n (%) 40 (54) 87 (63)
erm(AM)-positive isolates n (%) 34 (46) 48 (34.8)
mef(A) ⁄ (E)- and erm(AM)-positive isolates n (%) 0 3 (2.2)
Table 2. Antimicrobial susceptibilities of 74 macrolide-
non-susceptible Streptococcus pneumoniae isolates with dif-
ferent resistance genotypes from the year 2000 survey
Genotype Antibiotic
MIC range
(mg ⁄L)
MIC50
(mg ⁄L)
MIC90
(mg ⁄L)
Susceptiblea
(%)
erm(AM)
(n = 34)
Erythromycin 256 to >256 >256 >256 0
Penicillin 0.004–0.38 0.012 0.125 79.4
Ampicillin <0.016–1 <0.016 0.125 100
Ceftriaxone <0.002–0.38 0.008 0.125 100a
Cefepime <0.002–1 0.023 0.38 100a
mef(A) ⁄ (E)
(n = 40)
Erythromycin 2–48 16 32 0
Penicillin 0.008–2 0.023 1 50
Ampicillin <0.016–1.5 0.016 1 92.5
Ceftriaxone 0.006–1 0.023 0.5 100
Cefepime 0.012–1.5 0.047 1 95
aSusceptibility (mg ⁄L) was defined according to the recommendations supplied
with Etests as: erythromycin £1; penicillin £0.06; ampicillin £2; ceftriaxone (for non-
meningitis isolates) £1; and cefepime (for non-meningitis isolates) £1.
Table 3. Antimicrobial susceptibilities of 138 macrolide-
non-susceptible Streptococcus pneumoniae isolates with dif-
ferent resistance genotypes from the year 2003 survey
Genotypea Antibiotic
MIC range
(mg ⁄L)
MIC50
(mg ⁄L)
MIC90
(mg ⁄L)
Susceptibleb
(%)
erm(AM)
(n = 48)
Erythromycin 24 to >256 >256 >256 0
Penicillin 0.008–4 0.032 2 50
Cefuroxime <0.016–8 0.125 4 66.7
Ceftriaxone 0.008–1 0.032 0.75 100
Moxifloxacin 0.016–0.38 0.125 0.25 100
Telithromycin 0.008–0.5 0.03 0.125 100
Linezolid 0.047–2 0.75 1 100
mef(A) ⁄ (E)
(n = 87)
Erythromycin 2–64 16 32 0
Penicillin 0.016–8 1.5 4 9.2
Cefuroxime <0.016–16 4 8 21.8
Ceftriaxone 0.012–4 0.5 1 90.8
Moxifloxacin 0.064–0.38 0.125 0.19 100
Telithromycin 0.008–0.5 0.125 0.125 100
Linezolid 0.5–2 1 1.5 100
aSusceptibilities of three isolates harbouring both erm(AM) and mef(A) ⁄ (E) are
described in Results.
bSusceptibility (mg ⁄L) was defined according to the recommendations supplied
with Etests as: erythromycin £1; penicillin £0.06; cefuroxime sodium £0.5; ceftriax-
one (for non-meningitis isolates) £1; moxifloxacin £1; and linezolid £2.
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shown in Table 4. Major PFGE clones were
defined arbitrarily as clusters containing more
than five isolates and were represented by PFGE
patterns 1–5. In total, 38 (51.3%) of all isolates
belonged to these five predominant clones. The 13
indistinguishable isolates with PFGE pattern 1
were from five day-care centres, whereas the nine
isolates with PFGE pattern 2 (serotype 19F) were
identified in nine different day-care centres with
no apparent epidemiological link. Only one or
two PFGE clones were recognised in ten of 14
day-care centres where two or more macrolide-
non-susceptible pneumococcal isolates were iden-
tified, indicating an extensive spread of certain
clones within day-care centres.
Serotyping
The serotype distribution of the isolates studied is
shown in Table 5. In the year 2000 survey, the
proportion of the recovered serotypes included
in, or partially covered by, the seven-valent
conjugate pneumococcal vaccine was 85%
(Table 6), whereas 98.7% of isolates were covered
by the 23-valent polysaccharide vaccine. Within
the subgroup of macrolide- and penicillin-non-
susceptible isolates, 96.3% belonged to serotypes
related to (included in or partially covered by) the
seven-valent vaccine, with the most common
being 19F, 6A and 6B.
Serotypes 19F and 6A were the most prevalent
serotypes among macrolide- and penicillin-non-
susceptible isolates from the 2003 survey. Protec-
tion by the seven-valent conjugate pneumococcal
vaccine was an estimated 85.8% for this subgroup
of isolates, and 89.7% for isolates resistant to
more than three antibiotics. Overall protection
against the macrolide-non-susceptible isolates
from 2003 was 86% and 96.4% by the seven-
valent and the 23-valent vaccines, respectively.
Table 4. Pulsed-field gel electrophoresis (PFGE) clones
detected among 74 macrolide-non-susceptible isolates from
the year 2000 survey, and the correlation of PFGE clones
with serotypes and macrolide resistance determinants
PFGE clone
(no. of isolates)
Macrolide resistance
determinant Serotype(s) (n)
No. of DCCs
with the same clone
1 (13) mef(A) ⁄ (E) 14 5
2,2A (9) mef(A) ⁄ (E) 19F 9
3 (6) mef(A) ⁄ (E) 23F 1
4 (5) erm(AM) 19A 1
5 (5) erm(AM) 6B (4), 6A (1) 1
6 (4) erm(AM) 6A (2), 6B (2) 1
7 (3) erm(AM) 15C (2), 15B (1) 1
8 (3) mef(A) ⁄ (E) 6A (2), 6B (1) 2
9 (2) erm(AM) 6B 1
10 (2) mef(A) ⁄ (E) 15A (1), 15C (1) 1
11 (2) mef(A) ⁄ (E) 19F 1
12, 12A (2) mef(A) ⁄ (E) 23F 1
13, 13A (2) erm(AM) 6B 2
14 (1) erm(AM) 11A 1
15 (1) erm(AM) 23F 1
16 (1) erm(AM) 19A 1
17 (1) mef(A) ⁄ (E) 10A 1
18 (1) erm(AM) 6A 1
19 (1) erm(AM) 18A ⁄B 1
20 (1) erm(AM) 11A 1
21 (1) erm(AM) 19A 1
22 (1) erm(AM) 23F 1
23 (1) erm(AM) 6B 1
24 (1) erm(AM) 15B 1
25 (1) mef(A) ⁄ (E) 14 1
26 (1) mef(A) ⁄ (E) 6A 1
27 (1) erm(AM) 24A 1
28 (1) erm(AM) 6B 1
NT (1) erm(AM) 3 1
DDC, day-care centre; NT, non-typeable.
Table 5. Serotype distribution of macrolide-non-suscept-
ible Streptococcus pneumoniae isolates from 2000 and 2003
Serotype ⁄ serogroup
No. of isolates by year
2000 2003
14 14 15
6B 13 21
19F 11 37
23F 10 13
6A 7 26
19A 7 2
15C 3 1
15B 2 0
15A 1 1
18A ⁄B 1 3
Othera 5 15
Non-typeableb 0 4
aIncludes serogroup ⁄ serotypes 1, 3, 7, 8, 10A, 11A, 12, 20, 22, 23B, 24A, 33, and
13 ⁄ 28.
bOmni serum-negative.
Table 6. Distribution of macrolide-non-susceptible Strep-
tococcus pneumoniae isolates according to serotype
Serotype
2000 2003
n (%)
Cumulative
percentage n (%)
Cumulative
percentage
Seven-valent
included
14 14 (18.9) 19 15 (10.9) 11
6B 13 (17.6) 37 21 (15.2) 26
19F 11 (14.9) 52 37 (26.8) 53
23F 10 (13.5) 65 13 (9.4) 62
18C 0 0
9V 0 0
4 0 0
Partially
covered
6A 7 (9.5) 74 26 (18.8) 81
19A 7 (9.5) 84 2 (1.5) 83
18A ⁄B 1 (1.3) 85 3 (2.2) 85
23A ⁄B 0 1 (0.7) 86
9N 0 0
Non-vaccinea
serotypes
11 (14.9) 100 20 (14.5) 100
aSerotypes ⁄ serogroups other than those included in or partially covered by (cross-
reactive with) the seven-valent conjugate vaccine.
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Non-vaccine serogroups ⁄ serotypes identified
were (in descending order) 15C, 15B, 11A, 15A,
10A, 24A and 3 for the year 2000, and 8, 1, 20, 3, 7,
12, 15A, 15C, 22, 33 and 13 ⁄ 28 for the year 2003. In
the entire collection of isolates, serotypes 14, 19F
and 6A were encountered more frequently among
isolates showing the M resistance phenotype,
whereas serotypes 6B, 23F and 19A were associ-
ated more often with the MLSB resistance pheno-
type. No significant differences were observed
between the two study periods with respect to
serotype distribution of isolates exhibiting the
same phenotype (data not shown).
DISCUSSION
This study identified a statistically significant
increase in the frequency of macrolide-non-sus-
ceptible pneumococci colonising the nasopharynx
of healthy children in the Athens metropolitan
area, from 23% in 2000 to 30.3% in 2003 (p <0.05).
Also detected was a statistically significant in-
crease in the frequency of the macrolide- and
penicillin-non-susceptible subgroup of isolates
(from 34.8% to 76.8%, p <0.001), whereas the
proportion of macrolide-resistant and penicillin-
susceptible isolates decreased from 65.2% in 2000
to 30.2% in 2003 (p <0.001). The increase in
macrolide and penicillin co-resistance (from
3.4% to 48.6%, p <0.001) was one of the most
alarming findings of the study. On the basis of
these findings, the Hellenic Society for Infectious
Diseases and the Hellenic Society for Chemother-
apy issued guidelines for the treatment of com-
munity-acquired pneumonia in 2005, which
recommended that monotherapy with macrolides
should be restricted to a specific patient subgroup
(i.e., those without co-morbidities, without risk-
factors for drug-resistant S. pneumoniae, and with-
out severe illness).
Increased use of macrolides has been identified
as one of several risk-factors for increasing rates
of macrolide resistance [21]. According to data
provided by the National Organisation for Drugs,
total macrolide consumption in Greece increased
from 6.07 defined daily doses ⁄ 1000 inhabitants in
1999 to 9.34 defined daily doses ⁄ 1000 inhabitants
in 2003. In 2002, outpatient macrolide consump-
tion in Greece was reported to be the highest
among 26 European countries [22].
Various national and international surveillance
studies have demonstrated a high global preval-
ence of in-vitro macrolide resistance among
pneumococci [1]. In Europe, the European
Antimicrobial Resistance Surveillance System
(EARSS) has detected a consistent increase in
erythromycin non-susceptibility in almost all
participating countries between 1999 and 2001,
with an overall increase of 5.9% annually during
that period [23]. According to the EARSS 2004
annual report, the rates have continued to rise in
most participating countries (http://www.earss.
rivm.nl). Internationally, results from the Alexan-
der Project have revealed a global increase in the
frequency of macrolide resistance, from 16.5% in
1996 [24] to 24.6% by 1998–2000 [25]. The PRO-
TEKT Study demonstrated that erythromycin
resistance was higher than penicillin resistance
in all regions of the USA, but that it remained
stable at c. 30% during the 3-year period of the
study [26]. Nevertheless, there was considerable
geographical variation in resistance rates [27].
These data emphasise the need to monitor local
susceptibility trends on both a national and a
regional level.
The present study detected an absolute corre-
lation between macrolide resistance phenotype
and genotype, although in other large surveil-
lance studies, a minority of macrolide-resistant
isolates remain PCR-negative for erm and mef
genes, with mutations of ribosomal proteins
and ⁄ or 23S rRNA genes being identified as the
mechanism of macrolide resistance [4,27]. An-
other important observation of the present study
was the predominance of isolates displaying the
M phenotype and harbouring the mef(A) ⁄ (E)
gene. This is in contrast with the data from most
other European countries, where the spread of
macrolide resistance is associated mainly with
erm-positive strains [28–33]. However, the M
resistance phenotype, mediated by the mef(A) ⁄ (E)
gene, is predominant among macrolide-resistant
pneumococci in Canada [34] and the USA [27].
Recently, data from surveillance studies have
suggested that erythromycin MICs for mef-posit-
ive isolates may be increasing (>16 to >256 mg ⁄L),
probably as a result of additional resistance
mechanisms [27,30]. The present study also iden-
tified an upward shift in erythromycin MICs
towards 64 mg ⁄L in this subgroup of isolates
(Tables 2 and 3). A higher prevalence of penicillin
resistance was observed among mef(A) ⁄ (E)-posit-
ive isolates than among erm(AM)-positive isolates
during both study periods (50% vs. 20.6% in 2000,
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p <0.02, and 90.8% vs. 50% in 2003, p <0.001;
Tables 2 and 3). A higher prevalence of resistance
to ampicillin and cefepime was also observed in
the year 2000 survey, as well as to cefuroxime and
ceftriaxone in the year 2003 survey, among the
mef(A) ⁄ (E)-positive subgroups of isolates.
A new finding in this study was the identifica-
tion of a dual resistance mechanism (erm and mef
coexistence) in three isolates from 2003. These
isolates exhibited high-level resistance to erythro-
mycin and were non-susceptible to penicillin; two
were also non-susceptible to cefuroxime and
ceftriaxone and belonged to serotype 19F. All
three isolates were susceptible to moxifloxacin,
linezolid and telithromycin. This is the first report
of S. pneumoniae isolates carrying both the
mef(A) ⁄ (E) and the erm(AM) genes in Greece,
but recent data confirm the worldwide distribu-
tion and increasing prevalence of this genotype,
with particularly high rates in South Africa and
South Korea. Most of these isolates belong to one
major clonal group and show limited serotype
distribution, with serotypes 19F and 19A being
the most common [35]. Furthermore, such isolates
often exhibit resistance to multiple classes of
antibacterial drugs [35,36]. Their evolutionary
advantage has been attributed to the acquisition
of two mobile genetic elements, Tn1545 and
mega, together with their associated resistance
genes [37]. Thus, their introduction and potential
spread in Greece is of serious concern.
The PFGE results for the isolates from the
year 2000 indicated extensive spread of certain
macrolide-non-susceptible clones within, but not
between, day-care centres. An exception to this
observation was the dissemination of the second
most common clone (PFGE patterns 2 and 2A)
among nine day-care centres with no apparent
epidemiological link. This clone was macrolide
and penicillin co-resistant and belonged to
serotype 19F. The successful spread of this co-
resistant clone was an alarming finding. Sero-
type 19F was also the most prevalent serotype
among isolates from the year 2003 with dual
non-susceptibility.
Previous studies [38–40] have shown that the
seven-valent conjugate vaccine provides protec-
tion against cross-reactive or vaccine-related ser-
otypes. Assuming that serotypes 6A, 19A, 23A
and 23B are also covered by, or are cross-reactive
with, this vaccine, the theoretical coverage for the
macrolide-non-susceptible isolates was c. 85% in
both study periods. There was a theoretical
decrease in the coverage against macrolide- and
penicillin-non-susceptible isolates, from 96.3% in
2000 to 85.8% in 2003, but this was not statistically
significant. Since the majority of macrolide- and
penicillin-non-susceptible isolates in this study
belonged to vaccine-related serotypes, the preval-
ence of resistance among pneumococci might be
reduced by the use of pneumococcal vaccines. In
Greece, the seven-valent conjugate pneumococcal
vaccine was introduced during October 2004. The
results of future surveillance studies in Greece are
much anticipated, since there is evidence that the
vaccine could be responsible for a major decline
in the incidence of invasive disease and in
resistance rates [40–42]. However, there are also
concerns regarding possible serotype replacement
in pneumococcal clinical isolates [35,39,42,43].
In conclusion, this study detected important
trends in the evolution of macrolide resistance
among S. pneumoniae isolates colonising the naso-
pharynx of children in the Athens community.
Local surveillance studies remain an important
tool for following the evolution of pneumococcal
resistance and for guiding empirical treatment of
pneumococcal infections.
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